Colon cancer treatment is personalized based on stage, overall health and tumor characteristics. Early detection and accurate ...

The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer, NBC News reported. The test isn't meant to replace colonoscopies, but is ...

For years, a diagnosis of colon cancer meant potential surgery followed by a painful round of chemotherapy to kill the remaining cancer cells. One-size-fits-all treatment was normal. A new blood test ...

Postoperative cfDNA levels and ctDNA detection rates in patients with stage II colon cancer screened for CIRCULATE (AIO-KRK-0217, ABCSG). Development and validation of machine learning risk prediction ...

Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...

Researchers and physicians have grappled with the role of "adjuvant," or post-surgery, chemotherapy for patients with early-stage colon cancer, even for cancers considered high risk. Now researchers ...

A 3-year structured exercise program post-chemotherapy improved disease-free and overall survival in stage III or high-risk stage II colon cancer patients. Patients in the exercise program reported ...

The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...